Novogen to Conduct Shareholder/Investor Briefing in New York

SYDNEY, Jan. 7, 2015 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ:NVGN), an Australian/US biotechnology company, today announced that it will hold a public Briefing for shareholders and investors in New York on 18^th February 2015 at 2 pm New York time.

The briefing will be held at the Yale Club (Saybrook Room), 50 Vanderbilt Ave, Manhattan (opposite Grand Central Terminal).

The main purpose of the Briefing is to provide an opportunity for US shareholders to meet senior company executives and for the investment community at large to better understand the Company's intellectual property portfolio and commercial potential.

Dr Graham Kelly, Novogen Group CEO and Executive Chairman, will present an overview of the clinical and corporate strategies for the Novogen Group for 2015-2016.

Professor Gil Mor PhD MD of Yale Medical School will present a talk entitled "Cantrixil: A Novel Therapy to Target Cancer Stem Cells to Prevent Tumor Recurrence."

Dr Marc Symons PhD of the Feinstein Institute for Medical Research at North Shore-LIJ will present a talk entitled "Development of TRXE-009 for the Treatment of Brain Cancer."

Dr Andrew Heaton, Novogen VP Drug Design and Manufacturing, and Mr Robert Kennedy, Novogen VP Corporate Relations (US), also will be in attendance.

The details of the Briefing are contained in the January edition of the Novogen Newsletter released today and available on the Company's website.

People interested in attending will need to confirm by contacting [email protected]

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen group includes US-based CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial disintegration.

The ATM compounds target the micro-filament component of the cancer cell's cytoskeleton and have been designed to combine with anti-microtubular drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate ('Anisina').

Further information is available on our websites www.novogen.com

For more information please contact:

SOURCE Novogen Ltd

Related Links

http://www.novogen.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED